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Russian patients with hereditary coagulopathies to determine
quality of life. METHODS: Postal survey of 6309 patients using
EUROQoL-5D (EQ-5D) was made in December 2007–January
2008. The questionnaire was proposed to all registered patients
suffer from hereditary coagulopathies from 12 years old. The
data of ﬁve dimensions of the questionnaire (mobility, self-care,
usual activities, pain/discomfort anxiety/depression) and data
from the visual-analog scale was analyzed. RESULTS: A total of
1030 (16.3%) completed questionnaires were received by May
11, 2008. Forty-eight questionnaires were excluded from analy-
sis because of the absence of key elements. Data of 472 adult and
children 12 years old were analyzed; 462 questionnaires are
under analyses now. A total of 661 (10.5%) blank questionnaires
returned (due to death, changing place of living). A total of
67.1% of patients reported any problems (moderate or severe)
with mobility (no information about 1.5% of patients), 36.4% of
patients inform of any problems with self-care (no data about
1.3% of patients). A total of 63.6% of patients had difﬁculties
with usual activity (no data about 0.7% of patients). A total of
81.4% of patients report of presence of pain and discomfort (no
data about 0.8% of patients). A total 52.1% of patients report of
anxiety or depression (no information about 2.3% of patients).
The average value of quality of life according to the visual-analog
scale was 57.47. CONCLUSIONS: The intermediate results
of postal survey, investigating a quality of life in Russian
patients with hereditary coagulopathies, shows high rate of
problems with mobility, usual activity and high rate of pain and
discomfort.
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OBJECTIVES: Traditional iron overload treatment can be very
time-consuming for the patient, making it important to augment
clinical assessments with patient-reported outcomes. This study
investigated the link between satisfaction with ICT and health-
related quality of life (HRQoL). METHODS: As part of a ret-
rospective chart review and semi-prospective investigation,
patients with thalassaemia (n = 81), sickle cell disease (n = 23),
or myelodysplastic syndromes (n = 6) from eight study sites (four
per country: US (n = 60) and UK (n = 50)) completed the Satis-
faction with ICT instrument (SICT) and the Short Form 36-Item
Health Survey (SF-36) at one study visit. Patients were receiving
deferoxamine, deferiprone, or combined therapy. To explore the
associations between satisfaction and HRQoL, Pearson’s corre-
lation coefﬁcients were calculated between the SICT and SF-36.
A statistical signiﬁcant level of p  0.05 was applied. RESULTS:
Data from 110 iron overload patients undergoing ICT partici-
pated in the study (female 57.27% (n = 63); mean age 30.9
years). The SICT ‘Burden of ICT’ and ‘Side Effects of ICT’
domains signiﬁcantly correlated with all SF-36 domain and
summary scores (r = 0.29 to 0.45 and r = 0.21 to 0.41, respec-
tively) with the exception of ‘Side Effects of ICT’ and ‘Role-
Physical’ (r = 0.19). The SICT ‘Perceived Effectiveness of ICT’
domain signiﬁcantly correlated with SF-36 domains ‘General
Health’ (r = 0.23) and ‘Social Functioning’ (r = 0.24), whilst
‘Acceptability of ICT’ correlated with ‘Bodily Pain’ (r = 0.22)
and ‘General Health’ (r = 0.22). CONCLUSIONS: Satisfaction
with ICT provides prognostic information beyond standard clini-
cal and physiological assessments. Results indicated that as ICT
burden and side effects decreased, HRQoL increased. Further
research is warranted using clinical trial data to validate these
results. Clear a priori hypothesis could be developed and tested
using regressions or structural equation modelling.
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OBJECTIVES: To understand patients’ tolerability and per-
ception of the effectiveness of the BIB system. METHODS: A
paper-based survey was completed by 186 patients through 5
physician’s practices in Europe, Canada and South America.
Surveys were completed either in person or via phone by a health
care professional. Questions focused on patient demographics,
current or prior use of the BIB system, self reported weight loss,
and tolerability. Univariate analyses were performed to evaluate
the amount of weight loss, side effects associated with the BIB
system, patients’ overall satisfaction with the system, and the
likelihood of recommending it to others. RESULTS: Of the 186
respondents, 40% were currently using the BIB system. The
mean age of the population was 37 years (range 17–76 years).
The average weight loss for patients who had completed the full
6 months at the time of the survey was 17.7 kg. While during the
induction phase of using the BIB system, the majority of patients
experienced moderate to severe nausea and vomiting, but their
daily functioning was not greatly affected. While using the BIB
system, more than half of the patients experienced nausea,
cramping, and vomiting; however, most patients had complete
resolution of symptoms within 7 days. About 87% of the
patients were satisﬁed with the BIB system and 85% would
recommend it to others. Reasons for satisfaction included:
amount of weight loss and ability to effectively diet without
feeling hungry. CONCLUSIONS: Most patients were satisﬁed
with the BIB system, despite early side effects they experienced,
and would consequently recommend BIB to others.
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OBJECTIVES: To explore the perspectives of both physicians
and patients on how pain was assessed, managed and treated.
METHODS: Face to face semi-structured questionnaires were
administered with 70 physicians and 210 patients. Most of the
physicians were specialists (78.6%) and practiced at private hos-
pitals (61%). Patients were recruited through the physicians at
their consultation. RESULTS: Most patients were female (71%)
and aged less than 30 years were seen by GPs while the older ones
41–60 years, were seen by specialists. Lumbar/low back pain and
osteoarthritis were the most common pain encountered and one-
third of the patients suffered from pain for less than three weeks
before seeing doctors. Overall the patients were quite satisﬁed
with their doctors’ consultation time spent. However, the patients
who were treated by GPs perceived that their doctors did not
explain about the treatment options to the same level as physicians
claimed that their patients were informed. Regarding the types of
treatment, 93%physicians reported that they likely recommended
both pharmacological and non-pharmacological treatments but
the patients revealed that they received pharmacological treat-
ment only (47%) and 53% for the combination remedy. Factors
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affecting the physician prescribing decision included safety (96%),
efﬁcacy (90%), and cost (86%) of drug choice while the patients
viewed that efﬁcacy (86%), convenient dosage (53%), and safety
(42%) of a drug were their main concerns. About eight out of ten
patients reported that the sources of information for pain man-
agement were from specialists, friends/family, GPs and TV/Radio.
Nevertheless, most patients were not proactively discussing the
potential risks associated with prescription of NSAIDs with their
doctors. CONCLUSIONS: Different concerns and information
communicated by doctors may affect how it is perceived by
patients. Effective patient education is essential to encourage a
two-way communication between physician-patient to minimize
the negative outcomes and maximize the quality of care.
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OBJECTIVES: Health-related quality of life (HRQL) and its
impact upon productivity have not been well documented among
hemophilia patients, nor among their caregivers. This study of
hemophilia patients with inhibitors assessed patient and family
caregiver productivity and the impact of patient HRQL.
METHODS: Inhibitor patients who participated in a patient
forum were mailed a survey including questions on clinical and
demographic characteristics, aspects of medical care, HRQL (via
the SF-12 v2), and productivity. 53 of 90 surveys were returned.
Regression analyses assessed the association of patient and treat-
ment factors with HRQL mean physical (PCS) and mental (MCS)
composite summary scores and patient and caregiver productivity
(missed and low productivity days in the past year). RESULTS:
Patient mean age was 20.7 years (SD = 18.8), 88.5% were type A,
and 39.6% received on-demand therapy as their only treatment
mode. On-demand treatment (B = -0.336, P < 0.05) and number
of hemorrhages (B = -0.366, P < 0.05) were negatively associated
with PCS; and PCS was associated with patients’ missed work/
school days (IRR = 0.93, P < 0.001) and perceived impact on
daily activities (OR = 0.72, P < 0.05). PCS (IRR = 0.94, P < 0.01),
hemorrhages (IRR = 1.05, P < 0.05), surgery (IRR = 2.74,
P < 0.05), and younger age (IRR = 0.91, P < 0.01)were associated
with patients’ low productivity days. Patient surgery was associ-
ated with more caregiver missed days (IRR = 3.70, P < 0.05) and
more caregiver low productivity days (IRR = 8.99, P < 0.001).
Patient MCS was also associated with caregiver low productivity
days (IRR = 0.96, P < 0.01). CONCLUSIONS: Physical aspects
of HRQL among hemophilia patients with inhibitors impact their
daily activities and productivity; mental aspects of HRQL affected
the productivity of family caregivers.
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OBJECTIVES: Using the French national database of hospital
admissions in 2006, we estimated the economic burden for hos-
pitals of immune thrombocytopenic purpura (ITP) and ITP-
related splenectomy. METHODS: In France, public and private
hospital admissions are recorded in comprehensive administra-
tive databases that generate Diagnosis Related Groups (DRGs)
used for billing purposes, ICD10 diagnosis, and procedures
codes. Admissions for ITP were extracted. Admissions for ITP-
related splenectomy were identiﬁed by analyzing the surgical
procedures. Linking of each hospital stay and patient was made
to estimate the cost of ITP per patient. Admission costs from the
health care perspective were estimated from the 2007 ofﬁcial
DRG tariffs. RESULTS: In 2006, 10 561 hospital admissions for
ITP were recorded, of which 10,047 (95%) were in public or not
for proﬁt hospitals. In the public sector, 37 hospitals (i.e. 10% of
all public health care facilities) managed 50% of the caseload.
There were 269 admissions for ITP-related splenectomy, mainly
in the public sector (91%). Altogether 3612 patients in the public
sector required 9360 admissions or 2.80 in-patient admissions
per patient per year. In the private sector, 150 patients required
508 stays (3.4 hospital stays/patient/year). Based on these results,
the mean charge was €3653 per patient in public hospitals, and
€3177 per patient in private hospitals. The mean charge per
patient in public hospitals for ITP-related splenectomy was
€6367. These costs did not include expensive drugs, in particular
immunoglobulins or rituximab, which are excluded from the
DRGs reimbursement scheme in France and can result in extra
billing. CONCLUSIONS: Administrative databases allow the
estimation of the burden of ITP for hospitals. ITP and ITP-
related splenectomy were managed mostly in the public sector.
Splenectomy increased the cost per patient twofold. The cost of
expensive drugs to treat ITP must be evaluated in a separate
study.
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OBJECTIVES: Prior literature has suggested that the B domain
of FVIII may play a role in the rate of FVIII inactivation (Krenov
2006). Faster inactivation of recombinant B domain-deleted
factor VIII (BDD-rFVIII) could affect efﬁcacy during prophy-
laxis, potentially leading to increased risk for breakthrough
bleeds and higher FVIII utilization. The objective of this analysis
was to use real world data to determine whether patients treated
with BDD-rFVIII had higher annual FVIII utilization than
matched patients treated with full-length rFVIII (FL-rFVIII).
METHODS: Retrospective analysis of a large, US specialty phar-
macy database was conducted using 2006/2007 data. Patients
who were not receiving Immune Tolerance Therapy, had at least
six months of prescription activity, and did not switch brands
or treatment regimens were selected. BDD-rFVIII patients were
matched with up to 5 FL-rFVIII patients based on treatment
regimen (on-demand and prophylaxis), hemophilia severity and
age. The annualized number of international units (IU) dispensed
per kilogram was compared between both rFVIII groups using a
Wilcoxon Matched Pairs Test. Subgroup analysis was performed
by treatment regimen. RESULTS: Twenty-two BDD-rFVIII
patients met the inclusion criteria and were matched to 104
FL-rFVIII patients. Median annual IU/kg consumed for all BDD-
rFVIII and FL-rFVIII patients was 3630 and 3054 respectively
(p = 0.20). Subgroup analysis showed a statistically signiﬁcant
difference observed when comparing patients on a prophylactic
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